Kos Pharmaceuticals and SkyePharma terminate license agreement for flutiform – Trading Markets (press release)

Kos Pharmaceuticals and SkyePharma terminate license agreement for flutiform
Trading Markets (press release)
Flutiform is used for adult and adolescent asthma. Under the terms of the agreement, Kos has the right to perform further clinical development for
Abbott, Skyepharma Part Ways On Asthma Drug FlutiformPharmaLive (press release) (subscription)

all 2 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.